KR20170083136A - A2a 길항제 특성을 갖는 아미노피라진 화합물 - Google Patents
A2a 길항제 특성을 갖는 아미노피라진 화합물 Download PDFInfo
- Publication number
- KR20170083136A KR20170083136A KR1020177016281A KR20177016281A KR20170083136A KR 20170083136 A KR20170083136 A KR 20170083136A KR 1020177016281 A KR1020177016281 A KR 1020177016281A KR 20177016281 A KR20177016281 A KR 20177016281A KR 20170083136 A KR20170083136 A KR 20170083136A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- carboxamide
- pyrazine
- oxazol
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 **(*)C(C1=C(*)*C(*)=C(*)*1)=O Chemical compound **(*)C(C1=C(*)*C(*)=C(*)*1)=O 0.000 description 5
- AMSCZYUHBCLOHG-FSEBUJBSSA-N B/C(/C=C\NC(C#N)=N)=C/C Chemical compound B/C(/C=C\NC(C#N)=N)=C/C AMSCZYUHBCLOHG-FSEBUJBSSA-N 0.000 description 1
- ILUAZXSAAIWAJF-UHFFFAOYSA-N CCCOC(CN)SCC Chemical compound CCCOC(CN)SCC ILUAZXSAAIWAJF-UHFFFAOYSA-N 0.000 description 1
- BRBMDABLYHFXRX-UHFFFAOYSA-N Cc1cnc(C#N)nc1 Chemical compound Cc1cnc(C#N)nc1 BRBMDABLYHFXRX-UHFFFAOYSA-N 0.000 description 1
- SGSZFTVNOSOSQE-UHFFFAOYSA-N Cc1cnc(CN)nc1 Chemical compound Cc1cnc(CN)nc1 SGSZFTVNOSOSQE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081262P | 2014-11-18 | 2014-11-18 | |
| US62/081,262 | 2014-11-18 | ||
| PCT/US2015/060509 WO2016081290A1 (en) | 2014-11-18 | 2015-11-13 | Aminopyrazine compounds with a2a antagonist properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170083136A true KR20170083136A (ko) | 2017-07-17 |
Family
ID=56014406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177016281A Withdrawn KR20170083136A (ko) | 2014-11-18 | 2015-11-13 | A2a 길항제 특성을 갖는 아미노피라진 화합물 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10472347B2 (enExample) |
| EP (1) | EP3220910B1 (enExample) |
| JP (2) | JP6779204B2 (enExample) |
| KR (1) | KR20170083136A (enExample) |
| CN (1) | CN107106558A (enExample) |
| AU (1) | AU2015350315B2 (enExample) |
| BR (1) | BR112017010261A2 (enExample) |
| CA (1) | CA2967944C (enExample) |
| MX (1) | MX381180B (enExample) |
| RU (1) | RU2727805C2 (enExample) |
| WO (1) | WO2016081290A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202413340A (zh) * | 2016-07-12 | 2024-04-01 | 美商銳新醫藥公司 | 作為異位shp2抑制劑之2,5-雙取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪 |
| RU2019126455A (ru) | 2017-01-23 | 2021-02-24 | Революшн Медсинз, Инк. | Пиридиновые соединения в качестве аллостерических ингибиторов shp2 |
| SG11201906209SA (en) | 2017-01-23 | 2019-08-27 | Revolution Medicines Inc | Bicyclic compounds as allosteric shp2 inhibitors |
| US11066413B2 (en) | 2017-03-07 | 2021-07-20 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof |
| AU2018302178A1 (en) | 2017-07-18 | 2020-02-13 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| WO2019018584A1 (en) * | 2017-07-18 | 2019-01-24 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| EP3675856A4 (en) | 2017-08-31 | 2021-04-14 | Corvus Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR MODULATING THE A2B ADENOSINE RECEPTOR AND A2A ADENOSINE RECEPTOR |
| JP2020536881A (ja) | 2017-10-12 | 2020-12-17 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としてのピリジン、ピラジンおよびトリアジン化合物 |
| US11498923B2 (en) | 2017-12-13 | 2022-11-15 | Merck Sharp & Dohme Llc | Substituted imidazo[1,2-c]quinazolines as A2A antagonists |
| RU2020123241A (ru) | 2017-12-15 | 2022-01-17 | Революшн Медсинз, Инк. | Полициклические соединения в качестве аллостерических ингибиторов shp2 |
| SG11202101486RA (en) | 2018-08-16 | 2021-03-30 | Innate Tumor Immunity Inc | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
| US20200079793A1 (en) * | 2018-08-31 | 2020-03-12 | Corvus Pharmaceuticals, Inc. | Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor |
| WO2020106560A1 (en) | 2018-11-20 | 2020-05-28 | Merck Sharp & Dohme Corp. | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| KR20210093964A (ko) | 2018-11-20 | 2021-07-28 | 머크 샤프 앤드 돔 코포레이션 | 치환된 아미노 트리아졸로피리미딘 및 아미노 트리아졸로피라진 아데노신 수용체 길항제, 제약 조성물 및 그의 용도 |
| US12263171B2 (en) | 2018-11-30 | 2025-04-01 | Merck Sharp & Dohme Llc | 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use |
| CR20210271A (es) | 2018-11-30 | 2021-07-14 | Merck Sharp & Dohme | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso |
| CA3126735A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| US11254670B2 (en) | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| KR20210116550A (ko) | 2019-01-18 | 2021-09-27 | 누베이션 바이오 인크. | 아데노신 길항제로서의 헤테로시클릭 화합물 |
| TW202128650A (zh) * | 2019-10-11 | 2021-08-01 | 德商拜耳動物保健有限公司 | 作為殺蟲劑之新穎的雜芳基取代之吡𠯤衍生物 |
| CN111285798A (zh) * | 2020-04-09 | 2020-06-16 | 阿里生物新材料（常州）有限公司 | 一种（3-环丙基吡啶-2-基）甲胺盐酸盐的合成方法 |
| CN111423364A (zh) * | 2020-05-19 | 2020-07-17 | 阿里生物新材料（常州）有限公司 | 一种（3-环丙基吡啶-2-基）甲胺的合成方法 |
| EP3929189A1 (en) * | 2020-06-25 | 2021-12-29 | Bayer Animal Health GmbH | Novel heteroaryl-substituted pyrazine derivatives as pesticides |
| EP4313302A1 (en) | 2021-03-23 | 2024-02-07 | Bioage Labs, Inc. | Inhibitors of nlrp3 inflammasome |
| US11787805B2 (en) | 2022-01-28 | 2023-10-17 | BioAge Labs, Inc. | N-oxide inhibitors of NLRP3 inflammasome |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| US20250074870A1 (en) * | 2023-03-30 | 2025-03-06 | Brandeis University | Solid-solid phase change aromatic azo compounds, method of manufacture, and use for thermal energy storage and release |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
| CA2144330A1 (en) | 1993-07-27 | 1995-02-09 | Fumio Suzuki | A therapeutic agent for parkinson's disease |
| IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| EP1283839B1 (en) | 2000-05-26 | 2005-04-20 | Schering Corporation | Adenosine a2a receptor antagonists |
| SE0203754D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| WO2004111033A1 (en) | 2003-06-18 | 2004-12-23 | Astrazeneca Ab | 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator. |
| EP1678160A1 (en) * | 2003-10-27 | 2006-07-12 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
| US20060199828A1 (en) * | 2005-03-04 | 2006-09-07 | Georg Jaeschke | Pyrazine-2-carboxyamide derivatives |
| ES2270715B1 (es) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| US20120065205A1 (en) | 2009-06-01 | 2012-03-15 | Mercer Swati P | Pyrazine carboxamide orexin receptor antagonists |
-
2015
- 2015-11-13 KR KR1020177016281A patent/KR20170083136A/ko not_active Withdrawn
- 2015-11-13 MX MX2017006483A patent/MX381180B/es unknown
- 2015-11-13 CN CN201580073488.3A patent/CN107106558A/zh active Pending
- 2015-11-13 WO PCT/US2015/060509 patent/WO2016081290A1/en not_active Ceased
- 2015-11-13 CA CA2967944A patent/CA2967944C/en not_active Expired - Fee Related
- 2015-11-13 RU RU2017120853A patent/RU2727805C2/ru active
- 2015-11-13 JP JP2017526527A patent/JP6779204B2/ja not_active Expired - Fee Related
- 2015-11-13 BR BR112017010261-7A patent/BR112017010261A2/pt not_active IP Right Cessation
- 2015-11-13 US US15/525,788 patent/US10472347B2/en active Active
- 2015-11-13 AU AU2015350315A patent/AU2015350315B2/en not_active Ceased
- 2015-11-13 EP EP15861650.8A patent/EP3220910B1/en active Active
-
2020
- 2020-08-19 JP JP2020138418A patent/JP2020193211A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3220910B1 (en) | 2020-01-15 |
| MX2017006483A (es) | 2017-09-12 |
| RU2727805C2 (ru) | 2020-07-24 |
| AU2015350315A1 (en) | 2017-05-18 |
| CA2967944A1 (en) | 2016-05-26 |
| CN107106558A (zh) | 2017-08-29 |
| JP2017533946A (ja) | 2017-11-16 |
| US10472347B2 (en) | 2019-11-12 |
| RU2017120853A3 (enExample) | 2019-06-17 |
| CA2967944C (en) | 2020-11-17 |
| EP3220910A1 (en) | 2017-09-27 |
| JP6779204B2 (ja) | 2020-11-04 |
| WO2016081290A1 (en) | 2016-05-26 |
| JP2020193211A (ja) | 2020-12-03 |
| RU2017120853A (ru) | 2018-12-19 |
| EP3220910A4 (en) | 2018-04-25 |
| AU2015350315B2 (en) | 2020-06-25 |
| BR112017010261A2 (pt) | 2018-02-06 |
| MX381180B (es) | 2025-03-12 |
| US20180327385A1 (en) | 2018-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6779204B2 (ja) | Ａ２ａ拮抗薬特性を有するアミノピラジン化合物 | |
| EP2970313B1 (en) | Substituted 7-azabicycles and their use as orexin receptor modulators | |
| CN102548984B (zh) | Pi3激酶和/或mtor的抑制剂 | |
| KR101659193B1 (ko) | Btk 활성의 억제제로서의 헤테로아릴 피리돈 및 아자-피리돈 화합물 | |
| EP2590974B1 (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
| KR101656592B1 (ko) | 디히드로-벤조-옥사진 및 디히드로-피리도-옥사진 유도체 | |
| EP2785183B1 (en) | Triazolopyridinone pde10 inhibitors | |
| EP3717488B1 (en) | Substituted furanopyrimidine compounds as pde1 inhibitors | |
| KR20160056896A (ko) | Ｐｉｍ 키나아제 억제제로서 유용한 푸로- 및 티에노-피리딘 카복사미드 화합물 | |
| JP2021533179A (ja) | ピラジン化合物およびその使用 | |
| JP2017526622A (ja) | ３−アミノ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類 | |
| EP3060563A1 (en) | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors | |
| TW201329067A (zh) | 作為ｇｋａ活化劑之脲化合物 | |
| EA028816B1 (ru) | Модуляторы р2х7 | |
| WO2013142269A1 (en) | Imidazotriazinone compounds | |
| TW201726675A (zh) | M4毒蕈鹼乙醯膽鹼受體之異位調節劑6,7-二氫-5h-吡咯并[3,4-b]吡啶-5-酮 | |
| JP7357932B2 (ja) | Ｃｒｈｒ２拮抗薬としての縮合環状尿素誘導体 | |
| KR20160072133A (ko) | 4-아자인돌 유도체 | |
| CN115181092B (zh) | 吡嗪化合物和其用途 | |
| TW202506660A (zh) | Mrgprx2拮抗劑及其使用方法 | |
| HK40008526B (zh) | P2x7调节剂 | |
| HK40036192B (en) | Substituted furanopyrimidine compounds as pde1 inhibitors | |
| HK1219726B (en) | Substituted 7-azabicycles and their use as orexin receptor modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20170614 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20201111 Comment text: Request for Examination of Application |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20210614 |
|
| WITB | Written withdrawal of application |